Literature DB >> 23777885

Smart ligand: aptamer-mediated targeted delivery of chemotherapeutic drugs and siRNA for cancer therapy.

Xin Li1, Qinghe Zhao, Liyan Qiu.   

Abstract

Aptamers are a class of oligonucleotides that can specifically bind to different targets with high affinity. Since their discovery in 1980s, aptamers have attracted considerable interests in medical applications. So far, initial research using aptamers as delivery systems has produced exciting results. In this review, we summarize recent progress in aptamer-mediated chemotherapeutic drug and siRNA delivery systems in tumor treatment. With regard to chemotherapeutic drugs, the 2 main methods for targeted delivery using aptamers are as follows: aptamer-drug systems (in which aptamers directly deliver the drug both as a carrier and as a ligand) and aptamer-nanoparticles systems (in which nanoparticles function together with aptamers for targeted delivery of drugs). For delivery of siRNA, aptamers can be utilized by the following ways to facilitate targeting: (1) linked by a connector; (2) form a chimera; and (3) combined with nanoparticles. In co-delivery system, the advantages associated with the use of aptamers are beginning to become apparent also. Here, the challenges and new perspectives in the field of aptamer-mediated delivery have been discussed.
Copyright © 2013. Published by Elsevier B.V.

Entities:  

Keywords:  Aptamer; Cancer therapy; Drug delivery; Gene delivery; Nanoparticle

Mesh:

Substances:

Year:  2013        PMID: 23777885     DOI: 10.1016/j.jconrel.2013.06.006

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  29 in total

1.  Cationic lipid nanodisks as an siRNA delivery vehicle.

Authors:  Mistuni Ghosh; Gang Ren; Jens B Simonsen; Robert O Ryan
Journal:  Biochem Cell Biol       Date:  2014-04-22       Impact factor: 3.626

Review 2.  Cell-type-specific aptamer and aptamer-small interfering RNA conjugates for targeted human immunodeficiency virus type 1 therapy.

Authors:  Jiehua Zhou; John Rossi
Journal:  J Investig Med       Date:  2014-10       Impact factor: 2.895

3.  Cell-specific RNA aptamer against human CCR5 specifically targets HIV-1 susceptible cells and inhibits HIV-1 infectivity.

Authors:  Jiehua Zhou; Sangeetha Satheesan; Haitang Li; Marc S Weinberg; Kevin V Morris; John C Burnett; John J Rossi
Journal:  Chem Biol       Date:  2015-03-05

Review 4.  Aptamer-based targeted therapy.

Authors:  Guizhi Zhu; Xiaoyuan Chen
Journal:  Adv Drug Deliv Rev       Date:  2018-08-17       Impact factor: 15.470

Review 5.  Aptamer-Drug Conjugates.

Authors:  Guizhi Zhu; Gang Niu; Xiaoyuan Chen
Journal:  Bioconjug Chem       Date:  2015-07-14       Impact factor: 4.774

6.  Oligonucleotide aptamer-drug conjugates for targeted therapy of acute myeloid leukemia.

Authors:  Nianxi Zhao; Sung-Nan Pei; Jianjun Qi; Zihua Zeng; Swaminathan P Iyer; Pei Lin; Ching-Hsuan Tung; Youli Zu
Journal:  Biomaterials       Date:  2015-07-15       Impact factor: 12.479

7.  Aptamer-Conjugated Chitosan-Anchored Liposomal Complexes for Targeted Delivery of Erlotinib to EGFR-Mutated Lung Cancer Cells.

Authors:  Fengqiao Li; Hao Mei; Xiaodong Xie; Huijuan Zhang; Jian Liu; Tingting Lv; Huifang Nie; Yu Gao; Lee Jia
Journal:  AAPS J       Date:  2017-02-23       Impact factor: 4.009

Review 8.  [Research advances in the role of aptamers in the diagnosis and targeted therapy of pediatric cancer].

Authors:  Yi-Bin Zhang; Yan-Peng Wang; Jing Liu
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2018-05

9.  Direct validation of aptamers as powerful tools to image solid tumor.

Authors:  Olivier Martínez; Elisabeth Bellard; Muriel Golzio; Saad Mechiche-Alami; Marie-Pierre Rols; Justin Teissié; Vincent Ecochard; Laurent Paquereau
Journal:  Nucleic Acid Ther       Date:  2014-02-03       Impact factor: 5.486

Review 10.  RNA interference-based therapy and its delivery systems.

Authors:  Xiuhui Chen; Lingegowda S Mangala; Cristian Rodriguez-Aguayo; Xianchao Kong; Gabriel Lopez-Berestein; Anil K Sood
Journal:  Cancer Metastasis Rev       Date:  2018-03       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.